EMSCI involved in SCOPE ASIA 2012
To enhance the development of clinical trial and human study protocols that will accurately validate therapeutic interventions for spinal cord injury (SCI) and facilitate improved best practices.
Accomplishments to Date
Since 2006, SCOPE has:
- Hosted annual international workshops addressing SCI outcome choices in human studies.
- Published articles on spontaneous recovery of sensory & motor function after sensorimotor complete (AIS-A) SCI.
- Analyze alternative schemes for classification and stratification of incomplete SCI.
- Examine the feasibility of enrolling subjects with incomplete SCI in clinical studies.
Current and Past Contributing Partners
SCOPE participation is from industry, basic science, clinical research, academia, health care, federal government, not-for-profit foundations, and the SCI community. Since its inception, Partners include: AcordaTherapeutics, AlseresPharmaceuticals, American Paraplegia Society (APS), American Spinal Injury Association (ASIA), AsubioPharmaceuticals Inc., Clinical Assistance Programs (CapTrials), Cyberkinetics Inc., European Multicenter Study about Spinal Cord Injury (EMSCI), Geron Inc., International Campaign for Cures of Spinal Cord Injury Paralysis (ICCP), International Spinal Cord Society (ISCoS), National Institute on Disability and Rehabilitation Research (NIDRR), Neurometrix Inc.